## National Emerging Threats Initiative a National HIDTA Program




### **PDMPs & Emerging Threats**

John L Eadie

Public Health and PDMP Project Coordinator
Wednesday, October 4, 2017
Midwest HIDTA – Kansas City, MO

### What PDMPs Do

#### PDMPs: Generation 3.0 to 3.4



<sup>\*</sup>Other groups may also receive reports other than those listed

### Prescription Information PDMPs Collect from Pharmacies

- Patient identification:
  - Name & Address
  - o DOB & Gender
- Prescriber Information
- Dispensing Pharmacy Information
- Drug Information, e.g.
  - O NDC # = name, type, strength, manufacturer
- Quantity & date dispensed
- Source of payment (some states)

### PDMPs Providing Data Access to Law Enforcement

☐ Midwest HIDTA

Ш

|       | Open          |  |
|-------|---------------|--|
| State | Investigation |  |

- o lowa
- o Kansas
- o Missouri
- o Nebraska
- North Dakota X
- South Dakota X

Court/Grand Jury Process, e.g., Court Order, Subpoena, Search Warrant, Grand Jury

- X
- Χ
- Χ
- X

#### Law Enforcement Access to PDMP Data

- Until 2016 3 states law enforcement investigators direct access to PDMP database
  - CA, MA, WA
  - State Practice
- AR 2016 Implementing statute authorizing investigators' direct access
  - Consistent with other 3 states, but:
  - In law
  - Developing model for the nation
  - Being documented

### AR Law Enforcement & PDMP Access: *Designation*

- Statute: Arkansas Act 901- of 2015
- CEOs of law enforcement agencies must designate investigators assigned to investigate prescription drug diversion.
  - o Sheriff,
  - o Chief of Police,
  - Drug Task Force Supervisor,
  - Special Agent Supervisor in Charge

### AR Law Enforcement & PDMP Access: Training

- Agency CEOs and investigators must be trained:
- Instruct in advanced drug diversion investigations.
- Understanding of prescription drug abuse issues,
   PDMP and laws for use of PDMP data.
- Requirements and ethical considerations for the certified investigators' department CEOs.
- Must pass exam after training.
- Successful completion leads to investigator certification under Act 901.

### AR Law Enforcement & PDMP Access: *Use of Accounts*

- After certification, investigators can open PDMP accounts on-line.
- For each data request, investigator must certify it is for an open investigation.

### AR Law Enforcement & PDMP Access: Supervision / Accountability

- Agency CEOs have access so can audit investigators' requests for data.
- CEOs held accountable for investigators' use of data.
- Each agency must file annual report:
  - Verification inquiries were part of a lawful prescription drug diversion investigation.
  - Disposition of the investigation.

### Why is Law Enforcement Access to PDMP Data Important?

- Before access: a single case could take 4 or 5 weeks to prepare given the number of pharmacies and doctors involved.
- With access: can see whether a case should be investigated or not.
- With access: able to prepare a case for prosecution in only a week to ten days.
- Prescription Monitoring Program Center of Excellence. Notes from the Field. NF 2.3. Perspective from Kentucky: Using PMP Data in Drug Diversion Investigations. May 2011.

http://www.pdmpexcellence.org/sites/all/pdfs/NFF kentucky 5 17 11 c.pdf

# Mandates on Prescribers to Use PDMP Data

### Comprehensive Use Mandates

#### As of September 1, 2017:

24 states have enacted mandates on all prescribers to review PDMP data prior to at least initial opioid Rx:

#### State – Effective Date

- AK -- 7/2021
- AR 1/2019
- CA 6 mo. after Cures certified as ready- expected to be 2017
- CT 7/2015
- GA 7/2018
- KY 7/2012
- ME − 1/2017
- MA − 1/2016
- MD 7/2018
- NV 10/2015
- NH 9/2016
- NJ 11/2015

#### State – Effective Date

- NM 4/2014
- NY 8/2013
- NC -- After CSRS achieves certain improvements - TBD
- OH 4/2015
- OK 11/2015
- PA 6/2015
- RI -3/2015
- SC 5/2017
- TN 4/2013
- TX 9/2019
- WV 5/2013
- WI 4/2017

### Comprehensive Use Mandates - A

- Comprehensive mandates are objective:
  - Apply to all prescribers
  - Apply at least for all initial opioid prescriptions.
  - Drugs included:
    - All Schedule II, III and IV 8 states
    - Opioids and benzodiazepines 5 states
    - Opioids only 3 states
    - Schedule II and III drugs -- 1 state
    - Schedule II drugs for acute or chronic pain − 1 state

### Comprehensive Use Mandates – B

- Triggering events:
  - Initial Prescription for included drugs 18 states
  - For continued treatment:
    - All prescriptions 3 states
    - At least every 90 days 5 states
    - At least every four to six months 4 states
    - At least annually 3 states
    - No follow-up required 3 states

### Comprehensive Use Mandates – C


#### Exceptions to Mandates – most common:

- Short duration prescriptions:
  - 5 days or less if issued in Emergency Dept. 3 states
  - 7 days or less 3 states
     (in 1 excepted only if no refills)
  - 10 days or less 1 state
- Terminally III Patients
  - Terminal Illness 6 states
  - Terminal illness & under hospice care 2 states
- Hospital or long term care in patients 7 states
- If PDMP is inaccessible, e.g. electrical failure 5 states

### Provision for Prescriber Delegates

- Delegates can obtain PDMP reports for prescribers, when state law permits.
  - Prescribers set up subaccounts
  - Prescribers can audit delegates' use.
  - Prescribers are accountable for delegates' use.
- All states with comprehensive prescriber use mandates permit delegates.
- 47 states and DC authorize delegates.


### Reports Requested Kentucky PDMP: 2005 through 2015



### University of Kentucky Evaluation of Mandate – First year - A

- Pharmacist registrations increased 322% & queries increased by 124%.
- Prescriber registration increased 262%.
- Mean annual queries per prescriber increased 550 percent, from 34 queries in 2009 to 221 in 2013.
  - Increase continued thereafter previous slide.

### Kentucky Rx Submitted to PDMP: 2005 through 2015



### University of Kentucky Evaluation of Mandate – First year - B


- Both opioid and benzodiazepine prescribing decreased.
- A reduction in CII CIV Rx from 4 to 8%.
  - Reduction continued thereafter decrease is 10%
     by end of 2015 see previous slide.
- But a "chilling effect" on opioid prescribing did not appear.

### University of Kentucky Evaluation of Mandate – First Year - C

- High-dose oxycodone Rx decreased.
- # patients receiving Rx for combination of an opioid, benzodiazepine, and muscle relaxant, decreased by 30%.
- Hospital discharges and deaths decreased.
- While increase in heroin discharges and deaths increased, that started a year before HB1.
- Doctor Shopping decreased by over 50%.
- University of Kentucky study at: <u>http://www.chfs.ky.gov/NR/rdonlyres/8D6EBE65-D16A-448E-80FF-30BED11EBDEA/0/KentuckyHB1ImpactStudyReport03262015.pdf</u>

### NY State: Multiple Provider Episodes and PDMP Report Requests, October 2011- December 2015

#### Multiple Provider Episodes and PDMP Report Requests, October 2011 - December 2015



**Note:** Multiple provider episodes defined as patients using five or more prescribers and five or more dispensers within the month. **Source:** New York PDMP

Presented at National Rx Abuse & Heroin Summit 2017

### NY Mandate on Prescribers to Use PDMP Data

- Prescriber requests increased up to 100 times.
- Doctor Shopping (Multiple Prescriber Episodes) decreased 90% in 2 years.
- High Risk Prescribing decreased.
  - Combination opioid & benzodiazepine Rx down.
  - High risk opioids, e.g. >100 morphine mg equiv.
     down.

### New Data Elements: First Time Not From Dispensers

 Prescribers who sign pain treatment agreements with patients – add that into PDMP record so other prescribers will know.

-CA

 Law Enforcement and First Responders who administer Narcan add note into PDMP record so prescribers will know there was an OD (currently 90% who OD on opioids get more Rx). – WI

#### Other New Data Elements?

- Hospital Emergency Departments & EMS report all CS overdoses to PDMP?
- Objective findings of patients' behavior response to opioid's?
- Other clinical factors prescribers should know?

# Proactive / Unsolicited Prescription Monitoring Program Reports / Alerts

### **Unsolicited Reports and Alerts**

- PDMP data -- analyze to identify potential misuse and diversion, e.g.:
  - Potential doctor shopping,
  - Organized drug rings,
  - Prescription forgery
  - Pill Mills
  - Fraudulent sales of prescriptions by prescribers
- Send analyzed data rapidly to those who can intervene
  - Prescribers and Pharmacists
  - Law Enforcement
  - Health Professional Licensing Agencies

### Why Unsolicited Reports Are Essential

- MA PMP survey physicians receiving unsolicited reports:
  - Only 8% were "aware of all or most of other prescribers"
  - Only 9% said "based on current knowledge, including PMP report, patient appears to have legitimate medical reason for prescriptions from multiple prescribers."
- Alert prescribers of persons receiving more than 100 mg morphine equivalents of opioids per day
  - 8.9 times higher risk of death than low dose

### PDMPs Can Help Save Lives

- Identify and intervene persons doctor shopping
- West Virginia study of deaths 2005 to 2007:
  - Doctor shoppers 7 times more likely to die than non-shoppers

Pierce, et al; Doctor and Pharmacy Shoppers for Controlled Substances; Medical Care, Volume 00, Number 00, 2012

- If PMP identifies them and intervenes, lives can be saved
- Alerts / unsolicited report should be automated to distribute more rapidly

### States Issuing Unsolicited PDMP Reports - 2017

#### ■ Midwest HIDTA

|   | States      | <u>Prescriber</u> | s <u>Dispensers</u> | Licensing<br><u>Boards</u> | Law<br><u>Enforcement</u> |
|---|-------------|-------------------|---------------------|----------------------------|---------------------------|
| 0 | lowa        | X                 |                     |                            |                           |
| 0 | Kansas      | X                 | X                   | X                          | X                         |
| 0 | Missouri    |                   |                     |                            |                           |
| 0 | Nebraska    |                   |                     |                            |                           |
| 0 | North Dakot | ta X              | X                   |                            |                           |
| 0 | South Dakot | ta X              | X                   |                            |                           |

# Identify Areas of Highest Risk for Opioid Overdoses and Deaths, Including Heroin

### Tracking Rx Drug Misuse / Abuse

### States Allowing Use of Deidentified PDMP Data

#### ☐ Midwest HIDTA

o lowa Yes

o Kansas Yes

MissouriNo

o Nebraska No

o North Dakota Yes

South DakotaYes

### **Law Enforcement Seizure Data**




# Data from High Intensity Drug Trafficking Areas (HIDTAs) Performance Management Process (PMP)

#### Changes in Heroin Seizures by HIDTAs

#### In Kilograms


**United States – 2010-2016** 





## Changes in Stimulants Seizures by HIDTAs


In Kilograms (Cocaine and Methamphetamine Combined)
United States – 2010-2016



### Comparison of Heroin & Stimulant Seizures

Greatest *Increase* in Kilograms by HIDTA

United States - 2010-2016



### Summary of HIDTA Seizure Data

#### **Total Seizures 2010-2016**

Heroin 38,586.3 Kg

Stimulants Combined 596,998.7 Kg

Cocaine 469,144.6 Kg

Methamphetamine 127,854.1 Kg

15.5 Kg of Stimulants Seized for every 1.0 Kg of Heroin




## Prescription Drug Monitoring Program (PDMP) Data


### **Provided by State PDMPs**

### Opioid & Other Controlled Substances Prescription Rates for Representative States





### Stimulant Prescription Rates for Representative States Rate of Rx per 1,000 Population - 2010-2016



### Stimulant Prescriptions by Age Group

| • | Tennessee                       | # of Stimulant Rx |             |          |
|---|---------------------------------|-------------------|-------------|----------|
|   | <ul><li>Age Group</li></ul>     | <u>2010</u>       | <u>2016</u> | % change |
|   | <ul><li>19 or younger</li></ul> | 562,263           | 691,695     | 23.0%    |
|   | - 20 - 39                       | 269,166           | 478,312     | 77.7%    |
|   | <b>-</b> 40 <b>-</b> 59         | 166,129           | 293,548     | 76.7%    |
|   | - 60 - 119                      | 30,717            | 67,504      | 119.8%   |
|   | – Total                         | 1.028.275         | 1.531.059   | 48.9%    |

- TN stimulant Rx 2016 Rate = 230.2/1,000 population
- TN Stimulant Rx to children & youth 2016 est. = 361.1/1,000 population

### ARCOS Data from DEA – 2016




# Automation of Reports and Consolidated Ordering System (ARCOS) Drug Enforcement Administration (DEA)



### National Survey on Drug Use and Health (NSDUH) 2015

## Substance Abuse and Mental Health Services Administration (SAMHSA)

### New Initiates – Illicit Cocaine Use



### New Initiates – Nonmedical Use of Rx Stimulants




in (000s)



### New Initiates – Illicit Methamphetamine Use



- in (000s)






## Center for Disease Control (CDC) Wonder Reports & National Institute for Drug Abuse (NIDA)

2012 to 2015 Rise: Cocaine & Opioid






### Opioid involvement in cocaine overdose



Source: National Center for Health Statistics, CDC Wonder



### **Contact Information**

John L Eadie, MPA

Public Health & PDMP Project Coordinator
National Emerging Threats Initiative
National HIDTA Program
518-429-6397

jeadie@pdmpneti.org